These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16508156)

  • 61. Toxicity Study of a Self-nanoemulsifying Drug Delivery System Containing N-methyl pyrrolidone.
    Agrawal AG; Kumar A; Gide PS
    Drug Res (Stuttg); 2015 Aug; 65(8):446-8. PubMed ID: 25823509
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Controlled release of furosemide from the ethylene-vinyl acetate matrix.
    Cho CW; Choi JS; Shin SC
    Int J Pharm; 2005 Aug; 299(1-2):127-33. PubMed ID: 15967605
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.
    Bartow RA; Brogden RN
    Drugs; 1998 Feb; 55(2):303-22. PubMed ID: 9506248
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sustained Anti-inflammatory Effect of Resveratrol-Phospholipid Complex Embedded Polymeric Patch.
    Kalita B; Das MK; Sarma M; Deka A
    AAPS PharmSciTech; 2017 Apr; 18(3):629-645. PubMed ID: 27173988
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events.
    Cates CJ; Lasserson TJ; Jaeschke R
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006924. PubMed ID: 19370661
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The use of inhaled formoterol in the treatment of asthma.
    Berger WE
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):24-33. PubMed ID: 16892777
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of low- versus high-dose fluticasone propionate/formoterol fumarate combination therapy on AMP challenge in asthmatic patients: A double-blind, randomised clinical trial.
    Kanniess F; Diamant Z; Lomax M
    Pulm Pharmacol Ther; 2016 Apr; 37():65-72. PubMed ID: 26912209
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of penetration enhancers on the transdermal delivery of bupranolol through rat skin.
    Babu RJ; Pandit JK
    Drug Deliv; 2005; 12(3):165-9. PubMed ID: 16025846
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design and evaluation of a monolithic drug-in-adhesive patch for testosterone based on styrene-isoprene-styrene block copolymer.
    Ma J; Wang C; Luo H; Zhu Z; Wu Y; Wang H
    J Pharm Sci; 2013 Jul; 102(7):2221-34. PubMed ID: 23650152
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Enhanced transdermal delivery of atenolol from the ethylene-vinyl acetate matrix.
    Cho CW; Shin SC
    Int J Pharm; 2004 Dec; 287(1-2):67-71. PubMed ID: 15541913
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-<12 years).
    Pearlman DS; Eckerwall G; McLaren J; Lamarca R; Puu M; Gilbert I; Jorup C; Sandin K; Lanz MJ
    Ann Allergy Asthma Immunol; 2017 Apr; 118(4):489-499.e1. PubMed ID: 28256307
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development and evaluation of transdermal patches of celecoxib.
    Alam MI; Baboota S; Kohli K; Ali J; Ahuja A
    PDA J Pharm Sci Technol; 2009; 63(5):429-37. PubMed ID: 20158049
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
    Lipworth BJ; Dempsey OJ; Aziz I
    Chest; 2000 Aug; 118(2):321-8. PubMed ID: 10936119
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Percutaneous absorption enhancer applied to membrane permeation-controlled transdermal delivery of nicardipine hydrochloride.
    Seki T; Sugibayashi K; Juni K; Morimoto Y
    Drug Des Deliv; 1989 Jan; 4(1):69-75. PubMed ID: 2775447
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.
    Jonkers RE; Bantje TA; Aalbers R
    Respir Res; 2006 Dec; 7(1):141. PubMed ID: 17144916
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Development and evaluation of carvedilol-loaded transdermal drug delivery system: In-vitro and in-vivo characterization study.
    Kshirsagar SJ; Bhalekar MR; Mohapatra SK
    Drug Dev Ind Pharm; 2012 Dec; 38(12):1530-7. PubMed ID: 22356303
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Formulation and evaluation of ethylene-vinyl acetate copolymer matrix patches containing formoterol fumarate.
    Kakubari I; Shinkai N; Kawakami J; Uruno A; Takayasu T; Yamauchi H; Takayama S; Takayama K
    Biol Pharm Bull; 2006 Mar; 29(3):513-6. PubMed ID: 16508156
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of solvents on skin permeation of formoterol fumarate.
    Kakubari I; Nakamura N; Takayasu T; Yamauchi H; Takayama S; Takayama K
    Biol Pharm Bull; 2006 Jan; 29(1):146-9. PubMed ID: 16394528
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of ethylcellulose and 2-octyldodecanol additives on skin permeation and irritation with ethylene-vinyl acetate copolymer matrix patches containing formoterol fumarate.
    Kakubari I; Sasaki H; Takayasu T; Yamauchi H; Takayama S; Takayama K
    Biol Pharm Bull; 2006 Aug; 29(8):1717-22. PubMed ID: 16880631
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Enhanced transdermal absorption and pharmacokinetic evaluation of pranoprofen-ethylene-vinyl acetate matrix containing penetration enhancer in rats.
    Cho CW; Choi JS; Yang KH; Shin SC
    Arch Pharm Res; 2009 May; 32(5):747-53. PubMed ID: 19471890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.